Following considerable pressure over policies related to the accessibility of unpublished clinical trial data in its database and conflicts of interest for its officials (Hampton T. JAMA. 2011;306:593-595), the European Medicines Agency (EMA) is taking steps to increase transparency.
As a part of this effort, in July the EMA, the European counterpart to the US Food and Drug Administration (FDA), announced that it will release the agendas and minutes of its scientific committee meetings. “This latest initiative is an important part of opening up our operations, to reinforce the trust and reputation of the Agency as a public health body,” said Executive Director Guido Rasi, MD, in a press statement (http://tinyurl.com/bn4udam).
Graphic Jump Location
The European Medicines Agency, the European counterpart to the US Food and Drug Administration, has recently announced initiatives to increase transparency.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.